Jan 29, 2025, 18:07
The addition of pembrolizumab to neoadjuvant chemotherapy in the phase III KEYNOTE-756 – European Society for Medical Oncology
ESMO – European Society for Medical Oncology shared a post on LinkedIn:
“The addition of pembrolizumab to neoadjuvant chemotherapy in the phase III KEYNOTE-756 significantly improves the pathological complete response rate in patients with high-risk, early-stage ER+/HER2− Breast Cancer.
Read the full news on ESMO Daily Reporter.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 29, 2025, 17:41
Jan 29, 2025, 17:34
Jan 29, 2025, 17:21
Jan 29, 2025, 16:50
Jan 29, 2025, 16:46
Jan 29, 2025, 16:41
Jan 29, 2025, 15:35
Jan 29, 2025, 15:31
Jan 29, 2025, 15:27